Hematopoietic stem cell (HSC) transplantation is a potentially curative treatment for numerous hematological malignancies. The transplant procedure as performed today takes advantage of HSC trafficking; either egress of HSC from the bone marrow to the peripheral blood, that is, mobilization, for acquisition of the hematopoietic graft, and/or trafficking of HSC from the peripheral blood to bone marrow niches in the recipient patient, that is HSC homing. Numerous studies, many of which are reviewed herein, have defined hematopoietic regulatory mechanisms mediated by the 20-carbon lipid family of eicosanoids, and recent evidence strongly supports a role for eicosanoids in regulation of hematopoietic trafficking, adding a new role whereby eicosanoids regulate hematopoiesis. Shortterm exposure of HSC to the eicosanoid prostaglandin E 2 increases CXCR4 receptor expression, migration and in vivo homing of HSC. In contrast, cannabinoids reduce hematopoietic progenitor cell (HPC) CXCR4 expression and induce HPC mobilization when administered in vivo. Leukotrienes have been shown to alter CD34 þ cell adhesion, migration and regulate HSC proliferation, suggesting that eicosanoids have both opposing and complimentary roles in the regulation of hematopoiesis. As numerous FDA approved compounds regulate eicosanoid signaling or biosynthesis, the utility of eicosanoid-based therapeutic strategies to improve hematopoietic transplantation can be rapidly evaluated.
Introduction
Stem cell migration is a common feature of hematopoiesis, occurring both during development and throughout life. Hematopoietic stem (HSC) and hematopoietic progenitor (HPC) cells continuously traffic to and from their bone marrow niche, 1 and the egress of hematopoietic cells from bone marrow into the periphery can be facilitated by various agents, such as cytokines or chemotherapy, a process termed mobilization. 2, 3 Circulating HSCs can home to the bone marrow and lodge within specific microenvironmental niches that support their survival, self-renewal and differentiation, and only HSC homing to this bone marrow niche are able to sustain hematopoiesis long-term. 4, 5 These trafficking processes form the basis of modern hematopoietic transplantation, which is routinely used to treat patients with leukemias, cancer, and hematological and genetic diseases. Sources of HSC for transplant include bone marrow, mobilized peripheral blood (MPB) and umbilical cord blood (UCB). Although bone marrow was the traditional source of HSC for transplantation, MPB has become the preferred source for hematopoietic grafts, 6, 7 and the use of UCB for transplants is steadily increasing. 8 Hematopoietic reconstitution after transplantation is a multi-step process, but with some sources of HSCs, efficacy is limited by inadequate HSC number, inability to migrate/home to marrow niches, and poor engrafting efficiency and self-renewal. [9] [10] [11] Considerable research, much of which is discussed in this issue of Leukemia, has focused on pathways governing HSC trafficking, with the goal of understanding and translating these findings to improve hematopoietic transplantation. Research strategies designed to increase HSC mobilization from bone marrow to peripheral blood in order to obtain an enhanced MPB product, or to enhance homing of HSC into the recipient bone marrow for enhanced hematopoietic engraftment are being evaluated in pre-clinical and clinical models. Although cytokines, chemokine/chemokine receptor interactions and adhesion molecules have been the major targets of attention for improvement of HSC mobilization and homing, recent evidence has begun to elucidate the role of bioactive lipids as regulators of HSC migration. In particular, an emerging role for the 20-carbon lipid eicosanoids in hematopoietic trafficking suggests new avenues and therapeutic strategies for clinical improvements in hematopoietic transplantation. Here, we review what is known about eicosanoids and regulation of hematopoiesis and hematopoietic cell trafficking, present novel effects of eicosanoids on cell trafficking, and discuss potential strategies for improvement in hematopoietic stem cell transplantation based on modulation of eicosanoid signaling and/or synthesis.
Eicosanoids
The eicosanoid family of lipids include the prostaglandins along with prostacyclins and thromboxanes, leukotrienes and endocannabinoids, most of which are formed by oxidation of 20-carbon essential fatty acids. Eicosanoids affect all organs, tissues and cells.
12 Prostaglandin E 2 (PGE 2 ) is the primary metabolite of arachidonic acid and the most abundant eicosanoid. PGE 2 is a known mediator of cancer, fever, inflammation, atherosclerosis, blood pressure and strokes, ovulation and numerous other physiological systems (reviewed in Legler et al. 13 and Miller 14 ). All nucleated cells can synthesize prostaglandins, 14 which occurs in three steps: cleavage of arachidonic acid from phospholipids by phospholipase A 2 ; oxidation by the cyclooxygenase (COX1 and COX2) enzymes forming the unstable intermediate PGG 2 , with subsequent reduction to form PGH 2 ; and isomerization to mature prostaglandins by specific synthases [15] [16] [17] ( Figure 1 ). Non-steroidal anti-inflammatory drugs have been developed that inhibit COX enzymes with selective specificities for COX1 and COX2 [18] [19] [20] and their primary therapeutic effect is due to reduced PGE 2 biosynthesis. Based upon its chemical/metabolic instability, PGE 2 is thought to act locally in autocrine or paracrine fashion. 21 Within the bone marrow microenvironment, osteoblasts are a major source of PGE 2 22-24 and due to their physical proximity to hematopoietic cells in the niche, are likely a primary source of PGE 2 for paracrine regulation of stem and progenitor function. Macrophages and monocytes also possess strong PGE 2 biosynthetic capacity and we have previously shown that monocyte/macrophage-derived PGE 2 plays a physiological role in hematopoiesis. [25] [26] [27] The leukotrienes are biosynthesized by oxygenation of arachidonic acid by 5-lipoxygenase (LOX) and conversion to the unstable intermediate leukotriene A 4 (LTA 4 ), which is enzymatically hydrolyzed to LTB 4 or conjugated to glutathione forming the cysteinyl leukotriene LTC 4 . Leukotriene C 4 is subsequently converted to LTD 4 and LTE 4 ( Figure 1 ). Leukotriene formation occurs predominantly in inflammatory cells, including granulocytes, mast cells and macrophages, dendritic cells and B lymphocytes, 28 however, 12-LOX in platelets can convert LTA 4 produced by granulocytes to LTB 4 and lipoxins. 29 LTB 4 is produced at sites of inflammation and stimulates inflammatory leukocyte function. 30, 31 Like prostaglandins, the leukotrienes have a short half-life and are primarily involved in localized signaling.
The two main endocannabinoids, anandamide and 2-arachidonoyl glycerol (2-AG), are derivatives of arachidonic acid and are synthesized on demand. [32] [33] [34] However, as they are structurally similar to arachidonic acid, they are also substrates for COX enzymes, [35] [36] [37] resulting in alternative prostaglandins, with similar and novel effects. 35, 38 In addition, alternative prostaglandins can be readily metabolized into traditional prostaglandins via esterases or by dehydration. 38 Endocannabinoids can also be metabolized back to arachidonic acid through the action of fatty acid amide hydrolase or monoacylglycerol lipase 39 ( Figure 1 ). Recycling of endogenous endocannabinoids for new endocannabinoid biosynthesis can also occur. 40 Cannabinoids can stimulate the production of prostaglandins, 41 and likewise, PGE 2 can stimulate synthesis of 2-AG intermediates. 42 In summary, it is clear that eicosanoid biosynthesis is highly interactive and changes in biosynthesis or cell signaling pathways can alter overall eicosanoid balance and produce eicosanoids with similar or opposing functions.
PGE 2 : inhibitory or stimulatory to hematopoiesis?
Numerous studies by us and others spanning a period of more than 20 years from the early 1970s to the mid 1990s demonstrated that PGE 2 inhibits mouse and human myeloid progenitors cells, defined as colony-forming units (CFU)-granulocyte macrophage (CFU-GM) and CFU-macrophage (CFU-M), in vitro. 25, 26, [43] [44] [45] [46] A physiological role for PGE 2 in regulation of hematopoiesis, particularly, as a negative feedback regulator of myelopoiesis was further defined by studies in mice differing in PGE synthetic capacity; 27, 47 demonstration of abnormal PGE 2 responses in patients with leukemia; 43, 44, 46, 48, 49 prognostic association of disordered PGE 2 response in patients with myelodysplastic syndromes, 50 abnormal HPC response in patients cured of germ cell tumors, but progressing to acute leukemia; 51 and association of HPC response to PGE 2 with clinical response to interferon-g in patients with chronic myelogenous leukemia, chronic lymphocytic leukemia and Hodgkin's disease. 52 Not all studies, however, demonstrated an inhibitory effect of PGE 2 . Studies by Feher and Gidali 54 in 1974 showed that shortterm PGE 2 treatment of murine marrow cells in vitro increased the number of day 9 colony-forming unit spleen (CFU-S) in cell cycle. An increase in CFU-GM in S-phase was also seen after PGE pulse exposure of human marrow. 55 However, early studies evaluating in vivo dosing of PGE 2 in mice led to little or no increase in hematopoiesis. 56 We later demonstrated that repetitive in vivo PGE 2 administration inhibits CFU-GM frequency and cell cycle rate, and decreases marrow and spleen cellularity; [57] [58] [59] [60] whereas, short-term in vitro exposure to PGE 2 stimulated proliferation and cell cycle of quiescent cells and an increase in HPC, suggesting a stimulatory effect of PGE 2 on HSC. 61, 62 Further studies identified that dose, timing and duration of exposure were critical factors that determined positive or negative effects of PGE 2 .
Hematopoietic stem cell regulation by PGE 2
Interest in the regulatory roles of PGE 2 on hematopoiesis has recently increased and new studies have provided further insights into hematopoietic regulation and possible therapeutic applications with PGE 2 . Studies by North et al. 63 demonstrated that zebrafish embryos treated with a long-acting derivative of PGE 2 , 16,16 dimethyl-PGE 2 (dmPGE 2 ), had an increase in HSC production, whereas treatment with a non-steroidal antiinflammatory drug or COX knockout decreased HSC number during embryogenesis. In a zebrafish kidney marrow irradiation-recovery assay, dmPGE 2 increased kidney marrow repopulation, and ex vivo pulse exposure to dmPGE 2 increased the repopulating capacity of murine bone marrow cells in a competitive repopulation assay.
Although these studies demonstrated that PGE 2 affects HSCs, the mechanisms of action of PGE 2 on HSC were not determined. Wnt signaling, particularly in the contexts of hematopoietic stress, ageing or disease, plays an important regulatory role on HSCs (reviewed in Malhotra and Kincade 64 ). PGE 2 signaling through the EP2 and EP4 receptors results in phosphorylation of GSK-3 and increased b-catenin signaling, 65 which is downstream of the Wnt pathway and signaling specifically through the EP4 receptor has been shown to directly increase b-catenin suggesting synergistic cross-talk between COX2 and Wnt pathways. 66 In a follow-up study to those by North et al., PGE 2 signaling was shown to stabilize b-catenin in HSC and promote survival and proliferation during embryogenesis 67 demonstrating the in vivo significance of PGE 2 /Wnt interactions. Recently, we demonstrated that PGE 2 increases survival and proliferation of HSC, 68 and exposure to PGE 2 increased the anti-apoptotic protein survivin, which we have previously reported to be required for HSC to enter and progress through cell cycle, 69, 70 providing further mechanistic insights into the regulation of HSC by PGE 2 . In the context of pulse exposure to enhance hematopoietic transplantation, an important clinical translation of these described studies, we suggest a model in which PGE 2 facilitates enhancement of engraftment by a multipart mechanism. PGE 2 increases survival and self-renewal of HSC, through regulation of Wnt/b-catenin, survivin and possibly unidentified pathways, and increases CXCR4 expression enhancing homing and tethering of HSC in the bone marrow. The effect of PGE 2 on CXCR4 expression is critical to its ability to enhance HSC homing and engraftment and is described in further detail below.
Clinical trials are currently exploring the utility of ex vivo exposure to PGE 2 to enhance HSC engraftment. However, the ability to clinically modulate PGE 2 signaling in vivo may provide future therapeutic applications. An early study by Gidali and Feher in 1977 , primarily evaluating CFU-S, suggested that in vivo dosing of PGE 2 in mice led to little or no increase in hematopoiesis. 56 Extensive studies by our laboratory in the 1980s showed that repetitive in vivo PGE 2 administration inhibits CFU-GM frequency and cell cycle rate, and decreases marrow and spleen cellularity, [57] [58] [59] [60] however, utilization of competitive repopulation assays, definitive assays of HSC function, were not performed. In a recent study by Frisch et al., 71 repeated administration of PGE 2 for 16 days in vivo, expanded short-term, but not long-term, HSC in transplantation models. This regimen resulted in changes in the bone marrow niche, suggesting that the in vivo effects of PGE 2 on HSC and HPC may include indirect mechanisms. However, high doses of PGE 2 (B120 mg/mouse) were administered for extended periods of time, and control vehicle alone showed a approximately twofold increase in the percentage of lineage neg Sca-1 þ c-kit þ cells after 16 days, whereas PGE 2 treatment showed approximately a threefold increase over the same time period. 71 The effects of vehicle may be suggestive of inadvertent stress effects on hematopoiesis in this system. Moreover, the effects of PGE 2 on hematopoiesis at physiological concentrations may be different than those observed using pharmacological doses, as previously suggested. 56 Additional studies evaluating in vivo modulation of PGE 2 signaling, both at a receptor level and on biosynthesis, are necessary to fully explore the therapeutic potential of the prostaglandin pathway.
Hematopoietic regulation by other eicosanoids
The cannabinoids have been implicated in positive and negative effects on mature cells of the immune system; 72, 73 however, little is known about their effects on early hematopoietic cells. Anandamide can act as a synergistic growth factor for HPC 74 and has a pro-apoptotic effect on erythrocytes. 75 The endocannabinoid 2-AG also stimulates proliferation of HPC, 76 and has recently been shown to increase CFU-granulocyte/erythrocyte/ monocyte/megakaryocyte (GEMM) colony formation and cell migration. 77 Furthermore, activation of cannabinoid (CB) receptors on murine embryonic stem cells promotes hematopoietic differentiation. 78 In addition, non-Hodgkin's lymphoma cells have abnormally high levels of CB 2 receptor expression, 79 suggesting a potential proliferative role for cannabinoids.
Leukotrienes, like other eicosanoids, are produced in the marrow microenvironment, 80 and 5-LOX is found in HPC. 81 Whereas PGE 2 inhibits HPC proliferation and COX inhibitors enhance HPC production in vitro, the leukotrienes LTB 4 , LTC 4 and LTD 4 increase mouse and human HPC, [82] [83] [84] which is inhibited by 5-LOX inhibitors. 82, 83, 85 Moreover, PGE stimulates erythropoiesis, 86, 87 whereas LTB 4 and LTC 4 inhibit early-and late-erythroid progenitor cells. 88 Similarly, LOX inhibitors enhance erythropoiesis. In mice, dual COX inhibition enhances HPC recovery, 85 whereas selective 5-LOX inhibitors decrease CFU-GM and blast colony-forming cells. 82 The addition of LTB 4 to UCB cells cultured with growth factors enhances HPC proliferation with concomitant reduction in total CD34 þ cells, whereas the selective LTB 4 receptor antagonist CP105696 enhances production of CD34 þ cells and blocks HPC proliferation. 89 Overall, the available data suggest that LTB 4 signaling decreases HSC self-renewal and increases differentiation, whereas blocking LTB 4 receptor signaling increases HSC self-renewal and blocks their differentiation. This is in contrast to PGE 2 which enhances self-renewal, 68 and blockade of PGE 2
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Eicosanoids and hematopoiesisbiosynthesis enhances HPC production. 90 Whether enhanced HPC production observed upon inhibition of PGE 2 synthesis in vivo is a direct consequence of lack of PGE 2 -mediated HSC self-renewal remains to be determined. In any case, the use of PGE 2 or a leukotriene receptor antagonist or LOX inhibitor in the post-transplant setting may favor self-renewal. In addition, as blockade of COX enzymes makes more arachidonic acid available to the LOX pathway, 84 ,91 the use of a COX inhibitor post-transplant could promote HSC differentiation via direct inhibition of PGE 2 synthesis and/or increased synthesis of leukotrienes.
It is clear that prostaglandins, cannabinoids and leukotrienes have important roles in hematopoietic homeostasis, and evaluating their responses is critical to understanding eicosanoid function and development of eicosanoid-based therapeutic strategies for improvements in hematopoietic transplantation. The remainder of this article will focus on experimental systems that highlight the effects of eicosanoids on HSC and HPC in the context of how they can be used to affect trafficking to bone marrow, that is, homing, in order to improve HSC delivery, and directed egress from bone marrow, that is, mobilization, in order to obtain more HSC and HPC for transplant.
PGE 2 increases hematopoietic homing
Homing is a description of the ability of HSC and HPC to traffic from the peripheral blood, where they are injected intravenously for hematopoietic transplantation, to the bone marrow hematopoietic niche, where they can lodge, self-renew and differentiate to successfully repopulate the host's blood-forming system. Homing is a rapid process, which is measured in hours (or at most 1-2 days), 92 and should be separated from the concept of 'engraftment', which is more a description of the culmination of events pre-and post-homing of HSC. Homing of HSC to bone marrow appears to be regulated by the same processes responsible for HSC retention within the bone marrow niche, many of which are discussed in this issue of Leukemia. Adhesion molecules aid in trafficking, leukocyte rolling, transendothelial migration, and ultimate tethering in the marrow, and several adhesion molecules have been implicated as contributing to HSC and HPC tethering in the bone marrow hematopoietic niche; notably the integrins a4b1Fvery late antigen (VLA)-4, Figure 2b ).
Cannabinoids increase HPC mobilization
Recent evidence suggests that cannabinoids, signaling through the peripheral CB 2 receptor, inhibit SDF-1a induced and CXCR4-mediated chemotaxis of Jurkat T-cells 111 and activated human peripheral T-cells. 112 In addition, hematopoietic cell lines transfected with cannabinoid receptor migrate in response (a) Mouse SKL cells or human CD34 þ cells were treated on ice with 1 mM 16,16-dimethyl PGE 2 (dmPGE 2 ) or vehicle control for 2 h, washed and then re-suspended in media with 10% heat-inactivated fetal bovine serum and cultured at 37 1C for 16 h. After incubation, cells were washed, re-suspended in RPMI/0.5% BSA and allowed to migrate to 100 ng/ml recombinant mouse or human SDF-1a through a two-chamber, 6.5 mm diameter, 5 mm pore transwell. Cells migrating to the bottom chamber were enumerated by flow cytometry, and the percentage increase in migration over vehicle control determined. (b) SKL cells from CD45.1 and CD45.2 mice were isolated by fluorescence-activated cell sorting and treated with either dmPGE 2 or vehicle. Treated SKL cells were then transplanted competitively, headto-head into lethally irradiated (1100 cGys) CD45.1/CD45.2 hybrid mice, allowing for distinction of vehicle-treated, dmPGE 2 -treated and recipient SKL cells within the same animal. At 16 h post-transplant, hind limb bones were isolated and homed SKL cells determined by flow cytometry. Mean ± s.e.m., N ¼ 10 mice, each assayed individually, are shown.
to the endogenous cannabinoid, 2-AG, 113 and 2-AG can act as a chemoattractant for dendritic cells. 114 Stimulation of cannabinoid receptors reduces adhesion molecule expression, 115, 116 transendothelial migration of monocytes, 116 and regulates myeloid progenitor trafficking by alterating chemokines and chemokine receptors. 116, 117 Cannabinoids have also been reported to affect matrix metalloproteinase-9 production 118 in a number of cell lines and can modulate neutrophil function. 119, 120 Taken together, these data suggest that cannabinoids could play a role in hematopoietic mobilization, through interference in the SDF-1a/CXCR4 axis, reduction in adhesion and/or release of matrix metalloproteinase-9, which can degrade adhesion molecule interactions between HSC and HPC with the bone marrow niche, 121 or through other undefined mechanisms.
Although many of the above effects attributed to cannabinoids have been defined in mature blood cells, little research has explored their function on HSC and HPC. Using a number of different antibodies and flow cytometry, we were able to clearly detect CB receptors on immunophenotypically defined mouse and human HSC (not shown). We utilized the dual CB 1 and CB 2 agonist CP55940 122 and examined its effects on expression of CXCR4 and the adhesion molecule VLA-4 on SKL cells in vitro, compared with cells treated with dmPGE 2 . As we previously reported, short-term in vitro treatment with dmPGE 2 increased expression of CXCR4 on treated SKL cells (Figure 3a ). In addition, dmPGE 2 also increased SKL VLA-4 expression. In contrast, SKL cells treated with cannabinoids demonstrated significant reduction in both CXCR4 and VLA-4, suggesting that cannabinoids may be able to facilitate release of hematopoietic stem and progenitor cells from bone marrow niches.
In order to directly evaluate the effects of cannabinoid receptor agonists on HPC mobilization, BALB/c mice were treated with single injections of the CB 1 selective agonist ACEA, 123 the CB 2 selective agonist GP1a, 124 or the dual CB 1 and CB 2 agonist CP55940 and CFU-GM in peripheral blood were quantitated after 2 h. Single administration of the CB 2 selective agonist GP1a and the dual CB 1 /CB 2 agonist CP55940 mobilized CFU-GM to peripheral blood to a significant degree ( Figure 3b) ; whereas, the CB 1 selective agonist ACEA had only marginal mobilizing activity. In separate groups of mice, we also evaluated combination mobilization with G-CSF and the dual CB 1 /CB 2 agonist CP55940. Mice were mobilized with a standard 4-day regimen of G-CSF alone (50 mg/kg, bid Â 4 days) or the G-CSF regimen plus a single dose of CP55940 administered on day 5, 16 h after the last dose of G-CSF and 2 h prior to sacrifice. The addition of a single dose of CP55940 to the G-CSF regimen significantly increased CFU-GM mobilization compared with G-CSF alone (Figure 3c ). These data suggest that CB receptor ligation, particularly CB 2 , rapidly mobilizes CFU-GM, and that CB receptor activation enhances mobilization by G-CSF, likely by an effect on inhibition of CXCR4 signaling, or reductions in integrin adherence, as the kinetics of mobilization are consistent with the kinetics of mobilization by the CXCR4 antagonist AMD3100 and/or VLA-4 inhibitors. It should be noted that these effects of cannabinoids on CFU-GM mobilization are in contrast to a previously published study that showed that the CB 2 receptor mediates retention of immature B cells in bone marrow sinusoids, 125 perhaps suggesting cell-type specific mobilization responses. While these studies clearly indicate mobilization of HPC, further analysis of the full repertoire of HPC and HSC mobilized by cannabinoids, will aid in the potential future development of cannabinoid-/cannabinoid receptor-based mobilization strategies.
A role for leukotrienes in hematopoietic trafficking?
Leukotrienes are known mediators of allergic inflammation and asthma, however, there is little information on their role in hematopoietic stem and progenitor trafficking. LTB 4 has been shown to increase the migratory capacity of dendritic cells, 126, 127 and T-cell subsets. 126 It is also a potent chemoattractant for polymorphonuclear leukocytes and regulates transendothelial migration, 128, 129 which is at least partially mediated by regulation of adhesion molecules. Although LTB 4 þ progenitors, 130 which is mediated in part by regulation of VLA-4 and VLA-5 adhesion. 131 However, in vivo treatment with a LTD 4 receptor antagonist does not result in mobilization of CD34 þ cells 131 possibly due to low baseline levels of LTD 4 in steady state bone marrow. Evaluation of the use of leukotriene antagonism in combination with other mobilizing agents has not yet been explored. It remains to be determined if modulation of leukotriene activity either in vivo or ex vivo will have any efficacy in enhancing hematopoietic transplantation.
The Yin and Yang of eicosanoid regulation
In many physiological systems, prostaglandins, leukotrienes and endocannabinoids exhibit compensatory or opposing roles (reviewed in Table 1 ). The action of many non-steroidal antiinflammatory drugs, which block the production of PGE 2 , may also act by increasing signaling via endocannabinoids.
132 PGE 2 -glycerol has been shown to mobilize calcium, activate signal transduction pathways 133 and have neurological effects opposite of those induced by 2-AG. 134 Furthermore, prostaglandins and leukotrienes have been shown to have numerous opposing roles in pulmonary fibrosis 135 and in other systems they may act in a coordinate fashion. 136 It is particularly noteworthy that cannabinoid ligands block CXCR4 signaling 111, 112 and neutrophil migration, 120, 137 which one would expect to negatively affect homing, but enhance spontaneous release from marrow facilitating mobilization as we have demonstrated. In contrast, PGE 2 enhances CXCR4 expression and signaling, which facilitates hematopoietic homing, but may result in dampening of mobilization responses. Future studies evaluating combination of eicosanoid therapies, which take into account these opposing functions, are likely to lead to novel approaches to regulate hematopoietic trafficking and improve transplantation protocols. The current availability of numerous FDA approved pharmaceuticals that specifically regulate biosynthesis and signaling of prostaglandins, leukotrienes and cannabinoids will facilitate rapid translation of eicosanoid-based therapeutic research, both at the level of graft isolation or measured in terms of graft performance.
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